PIK3CA and neoplasm: In addition, testing of cfDNA demonstrated acceptable concordance (BRAF, 91%; EGFR, 99%; KRAS, 83%; PIK3CA, 91%) with standard of care mutation analysis of primary or metastatic tumor tissue obtained during clinical care.